Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
Anna Ludovica Fracanzani,Luca Valenti,Elisabetta Bugianesi,M. Andreoletti,Agostino Colli,Ester Vanni,Cristina Bertelli,Erika Fatta,D. Bignamini,Giulio Marchesini,Silvia Fargion +10 more
TLDR
Normal ALT is not a valuable criterion to exclude patients from liver biopsy, and Alterations in glucose metabolism and insulin resistance in subjects with normal ALT should also be considered in the selection of NAFLD cases for histological assessment of disease severity and progression.About:
This article is published in Hepatology.The article was published on 2008-09-01 and is currently open access. It has received 609 citations till now. The article focuses on the topics: Nonalcoholic fatty liver disease & Liver biopsy.read more
Citations
More filters
Journal ArticleDOI
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
Giulio Marchesini,Christopher P. Day,Jean-François Dufour,Ali Canbay,Valerio Nobili,Vlad Ratziu,Herbert Tilg,Michael Roden,Amalia Gastaldelli,Hannele Yki-Järvinen,Fritz Schick,Roberto Vettor,Gema Frühbeck,Lisbeth Mathus-Vliegen +13 more
TL;DR: The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system.
Journal ArticleDOI
Human fatty liver disease: old questions and new insights.
TL;DR: Recent mechanistic insights into nonalcoholic fatty liver disease are discussed, focusing primarily on those that have emerged from human genetic and metabolic studies.
Journal ArticleDOI
Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity
TL;DR: NAFLD warrants screening for cardio-metabolic risk and for progressive liver disease and the combination of three noninvasive tests with LB may optimally individuate patients with NASH, with or without advanced fibrosis.
Journal ArticleDOI
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Zobair M. Younossi,Zobair M. Younossi,Pegah Golabi,Leyla de Avila,James Paik,Manirath K. Srishord,Natsu Fukui,Ying Qiu,Leah Burns,Arian Afendy,Fatema Nader +10 more
TL;DR: Evidence is provided supporting high prevalence of NAFLD and NASH in patients with T2DM around the world and regional and global mean prevalence weighted by population size in each country were estimated and pooled using random-effects meta-analysis.
Journal ArticleDOI
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes,Quentin M. Anstee,María Teresa Arias-Loste,Heike Bantel,Stefano Bellentani,Joan Caballería,Massimo Colombo,Antonio Craxì,Javier Crespo,Christopher P. Day,Yuichiro Eguchi,Andreas Geier,Loreta A. Kondili,Daniela C. Kroy,Jeffrey V. Lazarus,Rohit Loomba,Michael P. Manns,Giulio Marchesini,Atsushi Nakajima,Francesco Negro,Salvatore Petta,V. Ratziu,Manuel Romero-Gómez,Arun J. Sanyal,Jörn M. Schattenberg,Frank Tacke,Junko Tanaka,Christian Trautwein,Lai Wei,Stefan Zeuzem,Homie Razavi +30 more
TL;DR: NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed, if obesity and DM continue to increase at current and historical rates.
References
More filters
Journal Article
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Scott M. Grundy,Diane M. Becker,Luther T. Clark,Richard S. Cooper,Margo A. Denke,James P. Howard,Donald B. Hunninghake,D. Roger Illingworth,Russell V. Luepker,Patrick E. McBride,James M. McKenney,Richard C. Pasternak,Neil J. Stone,Linda Van Horn +13 more
Journal ArticleDOI
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
David E. Kleiner,Elizabeth M. Brunt,Mark L. Van Natta,Cynthia Behling,Melissa J. Contos,Oscar W. Cummings,Linda D. Ferrell,Yao Chang Liu,Michael Torbenson,Aynur Unalp-Arida,Matthew M. Yeh,Arthur J. McCullough,Arun J. Sanyal +12 more
TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.
Journal ArticleDOI
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Hanna-Maaria Lakka,David E. Laaksonen,Timo A. Lakka,Leo Niskanen,Esko Kumpusalo,Jaakko Tuomilehto,Jukka T. Salonen +6 more
TL;DR: Cardiovascular disease and all-cause mortality are increased in men with the metabolic syndrome, even in the absence of baseline CVD and diabetes, according to the Kuopio Ischaemic Heart Disease Risk Factor Study.
Journal ArticleDOI
Nonalcoholic fatty liver disease.
TL;DR: Nonalcoholic fatty liver disease is associated with an increased risk of all-cause death, probably because of complications of insulin resistance such as vascular disease, as well as due to cirrhosis and hepatocellular carcinoma, which occurs in a minority of patients.